Search companies

Live

PYC THERAPEUTICS LIMITED (ASX: PYC)

Health care · News and insights

Price unavailable

Latest PYC announcements

Announcement Insights

PYC Meets Kidney-Trial Enrolment Target, With Key Data Still Due in 2027

PYC Therapeutics has met the interim target of enrolling 24 patients in the repeat-dose PYC-003 study for polycystic kidney disease, advancing toward its planned 2027 data readouts. The company had already said in October that kidney-study data was expected in 2027; the latest update specifies 12-month kidney-volume data from at least 24 patients, alongside results from repeat-dose and extension studies. A potential Phase 2/3 trial in 2028 remains subject to regulatory alignment and other conditions.

Updated 13 Nov 2026, 08:52 AM Sydney time
Share
SourcesPKD Program - Enrolment Target Met2026 Annual General Meeting Program and CEO PresentationResults of Annual General MeetingNotification regarding unquoted securities - PYCAnnual General Meeting - Conference LinkChange of Director's Interest NoticeChange of Director's Interest NoticeApplication for quotation of securities - PYCExercise of Options and Cleansing NoticeChange of Director's Interest NoticeQuarterly Activities/Appendix 4C Cash Flow Report
Comments

PYC Therapeutics Meets Kidney Disease Trial Enrolment Target

2026-11-13 · Health care

PYC: $1.84 -4.18% · MC: $1.9B

PYC Therapeutics has met its interim enrolment target of 24 patients in the Phase 1b repeat-dose study of PYC-003 for polycystic kidney disease and will continue recruiting. The company aims to report kidney volume data for at least 24 patients in calendar 2027 and progress to a potentially registrational Phase 2/3 trial in 2028, subject to regulatory alignment and patient dropout assumptions. It also expects to present data from the ongoing study and its open-label extension in 2027.

Updated 2026-11-13 11:01
Share
SourcesPKD Program - Enrolment Target Met
Comments

PYC Shareholders Approve Director Rights, But CEO Options Draw More Opposition

2026-11-12 · Health care

PYC: $1.91 +0.52% · MC: $1.9B

PYC Therapeutics shareholders passed all resolutions at the 2026 AGM, including awards of restricted and performance rights to CEO Rohan Hockings, which received strong support. Approval for up to 1.5 million options for Hockings drew more opposition, with about 28% of votes cast against; options for Professor Ian Constable received about 35% opposition.

Updated 2026-11-12 13:31
Share
Sources2026 Annual General Meeting Program and CEO PresentationResults of Annual General Meeting
Comments

PYC Therapeutics Director Buys Shares Ahead of AGM

2026-11-05 · Health care

PYC: $1.93 +4.32% · MC: $1.9B

PYC Therapeutics director Ian Constable bought shares on market through a family trust, increasing his indirect holding by about 16%. The purchase follows separate on-market acquisitions by directors Rohan Hockings and Peter Coleman in recent days. PYC also reminded shareholders that its AGM will be held next Thursday in Nedlands, Western Australia, with a Zoom option available through advance registration.

Updated 2026-11-05 16:23
Share
SourcesAnnual General Meeting - Conference LinkChange of Director's Interest Notice
Comments

PYC Therapeutics Director Rohan Hockings Buys Shares on Market

2026-11-03 · Health care

PYC: $1.80 -5.26% · MC: $1.9B

PYC Therapeutics director Rohan Hockings bought shares on market for approximately $206,000, increasing his direct ordinary shareholding by nearly 39%. The purchase follows director Peter Coleman's on-market acquisition of shares for approximately $202,000 last week. Hockings is also due to receive options and restricted rights under incentive plans, subject to shareholder approval.

Updated 2026-11-03 16:12
Share
SourcesChange of Director's Interest Notice
Comments

PYC Issues Shares After Option Exercise As Director Reports On-Market Buy

2026-10-30 · Health care

PYC: $1.88 -2.84% · MC: $1.9B

PYC issued shares after holders exercised options, while director Peter Coleman disclosed an indirect on-market acquisition of shares through a trust. The company issued 540,000 shares at $1.70 each, and Coleman’s disclosed purchase was valued at approximately $202,000.

Updated 2026-10-30 16:30
Share
SourcesExercise of Options and Cleansing NoticeApplication for quotation of securities - PYCChange of Director's Interest Notice
Comments

PYC Advances Four Genetic-Disease Drug Programs, With Kidney Trial Data Expected Next Year

2026-10-29 · Health care

PYC: $1.93 -1.78% · MC: $1.9B

PYC Therapeutics reported progress across four drug programs, including advancing its Phelan-McDermid candidate into required toxicology studies and moving its kidney-disease candidate into higher-dose and longer-term studies. The company said data from the ongoing kidney studies is expected in 2027, while early exploratory results from a single-dose study were presented after the quarter.

Updated 2026-10-29 08:45
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments